• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know
ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its lead product candidates are loncastuximab tesirine (ADCT-402), an ADC that is in a Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma, and Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL, as well as Phase I/II clinical trial in combination with ibrutinib for relapsed or refractory DLBCL and mantle cell lymphoma; and camidanlumab tesirine (ADCT-301), an ADC that is in a pivotal Phase II clinical trial for the treatment of relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma, and Phase Ib clinical trial for selected advanced solid tumors. The company also develops clinical-stage product candidates, such as ADCT-601 that is in a Phase Ia clinical trial for the treatment of selected advanced tumors; and ADCT-602, and a Phase I/II clinical trial for relapsed or refractory acute lymphoblastic leukemia, as well as preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of selected advanced solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, and Synaffix B.V. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
Please sign in first
none
none
none
| Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
|---|---|---|---|---|
|
No longer subject to file | 2010-12-08 | 0 | |
|
SWITZ ROBERT E PRESIDENT & CEO |
|
No longer subject to file | 2010-12-08 | 0 |
|
OWEN LAURA N VP, HR |
|
No longer subject to file | 2010-12-08 | 0 |
|
PFLAUM JEFFREY D VP, GC & SECRETARY |
|
No longer subject to file | 2010-12-08 | 0 |
|
No longer subject to file | 2010-12-08 | 0 | |
|
No longer subject to file | 2010-12-08 | 0 | |
|
No longer subject to file | 2010-12-08 | 0 | |
|
OBRIEN PATRICK D VP, PRESIDENT GCS |
|
No longer subject to file | 2010-12-08 | 0 |
|
No longer subject to file | 2010-12-08 | 0 | |
|
No longer subject to file | 2010-12-08 | 0 | |
|
No longer subject to file | 2010-12-08 | 0 | |
|
MATHEWS JAMES G VP, CFO |
|
No longer subject to file | 2010-12-08 | 0 |
|
No longer subject to file | 2010-12-08 | 0 | |
|
No longer subject to file | 2010-12-08 | 0 | |
|
PARRAN RICHARD B JR VP, PRESIDENT NS |
|
No longer subject to file | 2010-12-08 | 0 |
|
NEMITZ STEVEN GARY VP, CONTROLLER |
|
No longer subject to file | 2010-12-08 | 0 |
|
HARTWELL KIMBERLY SEYMOUR VP, GLOBAL GTM |
|
No longer subject to file | 2010-12-08 | 0 |
|
JURASEK CHRISTOPHER VP, PRESIDENT APS, CIO |
|
No longer subject to file | 2010-12-08 | 0 |
|
NICHOLSON HILTON M PRESIDENT NETWORK SOLUTIONS |
|
0 | 2008-12-15 | 0 |
|
0 | 2008-03-07 | 0 | |
|
BLANCHARD JOHN A III |
|
0 | 2008-03-07 | 0 |
|
HEMMADY GOKUL V VP & CFO |
|
76,800 | 2006-12-18 | 0 |
|
22,875 | 2006-06-05 | 0 | |
|
QUAY MARY E VP OPTS |
|
12,108 | 2006-03-03 | 0 |
| Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No current insider transactions | ||||||||||||||||
* -
| Code | Definition |
|---|---|
| A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
| C | Conversion of derivative security |
| D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
| E | Expiration of short derivative position |
| F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
| G | Bona fide gift |
| H | Expiration (or cancellation) of long derivative position with value received |
| I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
| J | Other acquisition or disposition |
| L | Small acquisition under Rule 16a-6 |
| M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
| O | Exercise of out-of-the-money derivative security |
| P | Open market or private purchase of non-derivative or derivative security |
| S | Open market or private sale of non-derivative or derivative security |
| U | Disposition pursuant to a tender of shares in a change of control transaction |
| W | Acquisition or disposition by will or the laws of descent and distribution |
| X | Exercise of in-the-money or at-the-money derivative security |
| Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
| Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
|---|
| Holder | Issuer | Net Short Position | Position Date | Origin |
|---|
